Literature DB >> 26261568

Expression of the EphA1 protein is associated with Fuhrman nuclear grade in clear cell renal cell carcinomas.

Xiaolin Wang1, Yushan Liu2, Guangxin Cao1, Xueliang Zhang1, Haifei Xu1, Hanfeng Xu3, Jiandong Wang4.   

Abstract

Aberrant expression of receptor tyrosine kinase EphA1 in malignant tissues has been reported. However, the expression profile of EphA1 in renal cell carcinoma (RCC) and its association with clinicopathological parameters remain unknown. The aim of this study was to determine the cancerous value of the EphA1 protein expression in patients with renal cell carcinomas. This study included 144 patients with clear cell RCC (ccRCC), 18 patients with chromophobe RCC and 6 patients with papillary RCC. The EphA1 protein was detected in RCC tissue samples by an immunohistochemical staining with a specific polycolonal antibody. The correlation of the expression of the EphA1 protein with clinicopathological parameters was evaluated. High level of the expression of EphA1 was observed in all normal renal tubes. The EphA1 protein was negatively or weakly expressed in 93 out of 144 ccRCC (64.6%) and positively expressed in 51 out of 144 ccRCC (35.4%). The high level expression of the EphA1 protein was significantly associated with younger patients (P<0.001), sex (P=0.016) and lower nuclear grade (P<0.001). No significant relation between the expression of EphA1 and tumor diameter was found (P=0.316). Positive expression of EphA1 was observed in all samples of chromophobe RCC and papillary RCC. Our data indicated that the EphA1 protein may be a new marker for the prognosis of ccRCC.

Entities:  

Keywords:  EphA1; Fuhrman nuclear grade; clear cell renal cell carcinoma; receptor tyrosine kinase

Mesh:

Substances:

Year:  2015        PMID: 26261568      PMCID: PMC4525902     

Source DB:  PubMed          Journal:  Int J Clin Exp Pathol        ISSN: 1936-2625


  19 in total

1.  Expression of EphA1 in gastric carcinomas is associated with metastasis and survival.

Authors:  Jiandong Wang; Yingchun Dong; Xulin Wang; Henghui Ma; Zhen Sheng; Guli Li; Guangming Lu; Haruhiko Sugimura; Xiaojun Zhou
Journal:  Oncol Rep       Date:  2010-12       Impact factor: 3.906

2.  A novel tumor grading scheme for chromophobe renal cell carcinoma: prognostic utility and comparison with Fuhrman nuclear grade.

Authors:  Gladell P Paner; Mahul B Amin; Isabel Alvarado-Cabrero; Andrew N Young; Hans J Stricker; Holger Moch; Robert H Lyles
Journal:  Am J Surg Pathol       Date:  2010-09       Impact factor: 6.394

Review 3.  Renal cell carcinoma.

Authors:  Paul Cairns
Journal:  Cancer Biomark       Date:  2010       Impact factor: 4.388

4.  Cancer statistics, 2014.

Authors:  Rebecca Siegel; Jiemin Ma; Zhaohui Zou; Ahmedin Jemal
Journal:  CA Cancer J Clin       Date:  2014-01-07       Impact factor: 508.702

5.  The role of aberrant VHL/HIF pathway elements in predicting clinical outcome to pazopanib therapy in patients with metastatic clear-cell renal cell carcinoma.

Authors:  Toni K Choueiri; André P Fay; Robert Gagnon; Ying Lin; Brittany Bahamon; Victoria Brown; Jonathan E Rosenberg; Thomas E Hutson; Katherine L Baker-Neblett; Christopher Carpenter; Yuan Liu; Lini Pandite; Sabina Signoretti
Journal:  Clin Cancer Res       Date:  2013-07-23       Impact factor: 12.531

6.  Investigation of tumor suppressor genes apart from VHL on 3p by deletion mapping in sporadic clear cell renal cell carcinoma (cRCC).

Authors:  Rashmi Bhat Singh; Pratibha S Amare Kadam
Journal:  Urol Oncol       Date:  2011-10-01       Impact factor: 3.498

7.  High expression of EphA1 in esophageal squamous cell carcinoma is associated with lymph node metastasis and advanced disease.

Authors:  Jiandong Wang; Jie Ma; Yingchun Dong; Zhen Shen; Henghui Ma; Xuan Wang; Shanshan Shi; Jinrong Wu; Guangming Lu; Libo Peng; Xiaojun Zhoud
Journal:  APMIS       Date:  2012-07-12       Impact factor: 3.205

8.  Increased expression of EphA1 protein in prostate cancers correlates with high Gleason score.

Authors:  Libo Peng; Haiyan Wang; Yingchun Dong; Jie Ma; Juanjuan Wen; Jinrong Wu; Xueqing Wang; Xiaojun Zhou; Jiandong Wang
Journal:  Int J Clin Exp Pathol       Date:  2013-08-15

9.  Downregulation of EphA1 in colorectal carcinomas correlates with invasion and metastasis.

Authors:  Yingchun Dong; Jiandong Wang; Zhen Sheng; Guoli Li; Henghui Ma; Xulin Wang; Rusong Zhang; Guangming Lu; Qiuju Hu; Haruhiko Sugimura; Xiaojun Zhou
Journal:  Mod Pathol       Date:  2008-11-14       Impact factor: 7.842

10.  Epigenetic silencing of EphA1 expression in colorectal cancer is correlated with poor survival.

Authors:  N I Herath; J Doecke; M D Spanevello; B A Leggett; A W Boyd
Journal:  Br J Cancer       Date:  2009-03-10       Impact factor: 7.640

View more
  4 in total

1.  The association between ephrin receptor-A1 expression and survival in patients with cancer: a meta-analysis.

Authors:  Hyun Min Koh; Bo Gun Jang; Dong Hui Lee; Chang Lim Hyun; Dong Chul Kim
Journal:  Transl Cancer Res       Date:  2022-06       Impact factor: 0.496

2.  ACAT1 and Metabolism-Related Pathways Are Essential for the Progression of Clear Cell Renal Cell Carcinoma (ccRCC), as Determined by Co-expression Network Analysis.

Authors:  Liang Chen; Tianchen Peng; Yongwen Luo; Fenfang Zhou; Gang Wang; Kaiyu Qian; Yu Xiao; Xinghuan Wang
Journal:  Front Oncol       Date:  2019-10-09       Impact factor: 6.244

3.  Identification of Biomarkers Associated With Pathological Stage and Prognosis of Clear Cell Renal Cell Carcinoma by Co-expression Network Analysis.

Authors:  Liang Chen; Lushun Yuan; Kaiyu Qian; Guofeng Qian; Yuan Zhu; Chin-Lee Wu; Han C Dan; Yu Xiao; Xinghuan Wang
Journal:  Front Physiol       Date:  2018-04-18       Impact factor: 4.566

4.  Oncogenic miR-425-5p is associated with cellular migration, proliferation and apoptosis in renal cell carcinoma.

Authors:  Jing Quan; Yawen Li; Xiang Pan; Yulin Lai; Tao He; Canbin Lin; Liang Zhou; Liwen Zhao; Shuolei Sun; Yu Ding; Lingzhi Tao; Yimin Hu; Xionghui Wu; Zebo Chen; Fangting Zhang; Jing Ye; Liangchao Ni; Yongqing Lai
Journal:  Oncol Lett       Date:  2018-06-11       Impact factor: 2.967

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.